Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference

Pittsburgh, July 31, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will present a corporate and clinical update at the Canaccord Genuity Annual Growth Conference on August 10, 2017 at 1:00pm ET at the InterContinental Hotel in Boston, MA. A live and archived webcast of the presentation will be available on the company’s events webpage.  

CT1812, Cognition’s first-in-class small molecule designed to displace beta amyloid oligomers, has recently completed patient enrollment in a Phase 1b/2 clinical study in patients with mild-to-moderate Alzheimer’s disease. The status and timeline for this clinical trial, as well as the results from a drug-drug interaction study of CT1812, which were presented recently at the Alzheimer’s Association International Conference in London, will be discussed at the Canaccord Genuity Conference. 

About Cognition Therapeutics, Inc.

Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule. This highly brain penetrant compound targets the sigma-2/PGRMC1 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. In Cognition’s recently completed Study COG0102, patients with mild-to-moderate Alzheimer’s disease are being randomized to one of three doses of CT1812 or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812.  Detailed results of this Phase 1b/2 study are anticipated to be announced at the CTAD (Clinical Trials on Alzheimer's disease) meeting in Boston in November 2017.  Additional information about Cognition may be found online at http://www.cogrx.com. 

Cognition Therapeutics
[email protected]

Aline Sherwood
Scienta Communications
[email protected]